Scholar Rock reports FY2023 net loss of $165.8M; cash $280M; SAPPHIRE data expected 4Q 2024

Scholar Rock Holding Corp

Net loss $165.8M ($1.99/share) vs $134.5M ($2.26/share) in FY2022; no revenue vs $33.2M prior year.
R&D spend $121.9M, G&A $49.4M; cash $280M expected to fund operations into 2H 2025.
Phase 3 SAPPHIRE trial (apitegromab in SMA) topline data on track for 4Q 2024; potential launch 2025 if approved.
FDA cleared IND for Phase 2 obesity trial of apitegromab + GLP-1 RA; start mid-2024, data mid-2025.
Appointed Katie Peng to board; promoted Mo Qatanani to CSO in Feb 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Scholar Rock Holding Corp reported the full year ended December 31, 2023 results: net income $165.8 million or $1.99 per share, EPS $1.99 per share.

Period: the full year ended December 31, 2023
Net income: $165.8 million or $1.99 per share
EPS: $1.99 per share
Result: reported results

Exact text from the filing

Full Year 2023 Financial Results For the full year ended December 31, 2023, net loss was $165.8 million or $1.99 per share

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Scholar Rock Holding Corp filing history →

Source: SEC EDGAR

accession 0001104659-24-035865

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.